y10B Antibody

What is Y10B antibody and what specific targets does it recognize?

Y10B is a monoclonal mouse IgG3 kappa antibody that specifically recognizes ribosomal RNA (rRNA). The antibody was originally raised against whole 5.8S ribosomal RNA and demonstrates high specificity for rRNA with no cross-reactivity with other RNA species . This specificity makes Y10B particularly valuable for ribosomal research and nucleolar studies where distinguishing rRNA from other cellular RNAs is essential.

The antibody's high specificity enables researchers to accurately detect and localize ribosomal components within cells, providing a reliable tool for studying ribosome biogenesis, nucleolar organization, and rRNA processing. Importantly, Y10B's epitope recognition appears to be conserved across diverse organisms, making it versatile for comparative studies across species .

What is the reactivity profile of Y10B antibody across different species?

Y10B antibody demonstrates remarkable cross-species reactivity, making it an exceptionally versatile tool for comparative studies. According to validated experimental data, Y10B definitively reacts with human, mouse, and bacterial rRNA . This broad reactivity extends to all eukaryotic species, with scientific literature specifically documenting successful applications in:

• Human cell lines (including HeLa and LN229)

• Mouse tissues and cell lines (including NIH-3T3 fibroblasts)

• Rat samples

• Avian specimens (specifically chicken)

• Fish models

• Plant materials

• Various bacterial species

The conserved nature of the epitope recognized by Y10B accounts for this extensive cross-reactivity, reflecting the evolutionary conservation of ribosomal RNA structures across diverse taxa .

What are the validated applications for Y10B antibody in research settings?

Y10B antibody has been validated for numerous research applications, providing researchers with a versatile tool for studying ribosomal RNA in multiple experimental contexts. The validated applications include:

The antibody is available in multiple formats including unconjugated (BSA-free), biotin-conjugated, and DyLight 350-conjugated versions, expanding the range of detection methods available to researchers .

What is the recommended protocol for immunocytochemistry/immunofluorescence using Y10B antibody?

The following protocol has been validated for optimal results when using Y10B antibody for immunocytochemistry/immunofluorescence:

• Sample Preparation:

  • Culture cells on appropriate coverslips or chamber slides

  • Fix cells with -20°C methanol for 10 minutes (preferred fixation method based on validated results)

  • Alternative fixation: 4% paraformaldehyde followed by permeabilization with 0.1% saponin

• Antibody Incubation:

  • Block with appropriate blocking buffer (typically 1-5% BSA in PBS)

  • Incubate with Y10B antibody at 5 μg/ml concentration

  • Optimal incubation: overnight at 4°C

  • For conjugated versions (e.g., biotin-conjugated, catalog #NB100-662B), proceed to detection step

  • For unconjugated versions, apply appropriate secondary antibody

• Detection and Visualization:

  • For biotin-conjugated Y10B: Use streptavidin conjugated to desired fluorophore (e.g., DyLight 550)

  • For direct conjugates (e.g., DyLight 350): No additional detection reagent required

  • Counterstain nuclei with DAPI

  • Mount with appropriate anti-fade mounting medium

• Imaging Parameters:

  • Recommended: 100X objective for optimal resolution

  • Digital deconvolution can enhance image quality

  • Typical pattern: Strong nucleolar and cytoplasmic staining reflecting rRNA localization

This protocol has been successfully implemented in various cell types including HeLa cells and NIH-3T3 mouse fibroblasts as documented in the scientific literature .

How should Y10B antibody be optimized for flow cytometry applications?

Flow cytometry with Y10B antibody requires careful optimization of intracellular staining procedures. The following protocol has been validated in research settings:

• Cell Preparation:

  • Harvest cells using standard procedures

  • Wash cells in PBS to remove media components

  • Create single-cell suspensions (critical for accurate analysis)

• Fixation and Permeabilization:

  • Fix cells with 4% paraformaldehyde

  • Permeabilize with 0.1% saponin (gentle permeabilization agent preferred for RNA epitopes)

  • Alternative permeabilization agents may include 0.1-0.5% Triton X-100 or commercial permeabilization buffers

• Antibody Staining:

  • Use Y10B antibody at 5 μg/ml concentration (optimal working concentration established in validation studies)

  • Incubate for 30 minutes at room temperature

  • For biotin-conjugated antibody (NB100-662B), follow with streptavidin-fluorophore conjugate (e.g., R-Phycoerythrin)

  • Include matched isotype control (Mouse IgG3 Kappa) at equivalent concentration

• Data Acquisition and Analysis:

  • Acquire at least 10,000 events per sample

  • Gate on intact cells using FSC/SSC parameters

  • Compare signal to isotype control to establish positive population

  • rRNA staining typically appears as a positive shift in the entire population rather than discrete positive/negative populations

This methodology has been successfully implemented in HeLa cells as documented in the literature, with clear differentiation between specific staining and isotype control .

What are the critical considerations when using Y10B antibody for immunoprecipitation of rRNA?

Immunoprecipitation (IP) with Y10B antibody presents unique challenges due to the nature of RNA targets compared to protein immunoprecipitation. The following critical considerations should be addressed:

• RNase-Free Conditions:

  • Use RNase-free reagents and DEPC-treated water throughout

  • Include RNase inhibitors in all buffers (typically 1 U/μl)

  • Pre-clean all surfaces with RNase decontamination solution

• Cross-linking Considerations:

  • For stable capture of RNA-protein complexes, consider formaldehyde cross-linking (1% for 10 minutes at room temperature)

  • For native conditions, optimize lysis buffers to maintain RNA-protein interactions

• Antibody Binding:

  • Pre-conjugate Y10B antibody to appropriate beads (Protein G or Protein A/G)

  • Recommended antibody concentration: 2-5 μg per IP reaction

  • For co-immunoprecipitation studies, consider the biotin-conjugated version (NB100-662B) with streptavidin beads

• Elution and Analysis:

  • For RNA analysis: Perform protein digestion with proteinase K followed by RNA purification

  • For protein co-IP studies: Use standard SDS elution buffers

  • Consider specialized techniques like CLIP (Cross-Linking Immunoprecipitation) for precise mapping of RNA-protein interaction sites

• Controls:

  • Input controls (5-10% of starting material)

  • Isotype control antibody (Mouse IgG3 Kappa)

  • No-antibody control to assess non-specific binding

The Y10B antibody has been successfully used for immunoprecipitation across multiple species, making it valuable for comparative rRNA studies. Its high specificity for rRNA ensures minimal cross-reactivity with other RNA species during immunoprecipitation experiments .

How can Y10B antibody be employed to study nucleolar stress in cancer models?

Y10B antibody serves as a powerful tool for investigating nucleolar stress in cancer models by enabling precise detection of changes in rRNA levels and localization patterns. Research has demonstrated that:

• Nucleolar Stress Detection:

  • Y10B antibody can visualize nucleolar disruption and reorganization under stress conditions

  • Changes in rRNA distribution (nucleolar to nucleoplasmic) can be quantified using immunofluorescence with Y10B

  • Flow cytometry with Y10B provides quantitative assessment of total cellular rRNA content changes during stress response

• Application in Glioblastoma Research:

  • Studies have utilized Y10B to demonstrate that inhibition of the de novo pyrimidine biosynthesis pathway causes nucleolar stress in glioblastoma cells

  • Researchers used Y10B antibody to monitor 47S pre-rRNA levels following DHODH inhibition with brequinar

  • Quantitative analysis revealed that 0.1 μM brequinar treatment significantly reduced rRNA transcription, while lower concentrations (0.01 μM) were insufficient to affect rRNA levels

• Experimental Design Considerations:

  • When studying nucleolar stress, combine Y10B staining with other nucleolar markers (fibrillarin, nucleolin) to comprehensively assess nucleolar integrity

  • Time-course experiments with Y10B can track the progression of rRNA disruption following treatment

  • Co-staining with cell cycle markers helps differentiate between treatment-induced effects and cell cycle-related changes in rRNA content

• Quantitative Assessment Protocol:

  • Capture high-resolution images of treated and control cells stained with Y10B

  • Measure nucleolar:nucleoplasmic signal ratio as indicator of nucleolar stress

  • Correlate with other functional readouts (cell proliferation, apoptosis markers)

  • For flow cytometry, monitor median fluorescence intensity shifts in the entire population

Recent research has demonstrated that cancer cells, particularly glioblastoma cells showing higher expression of enzymes involved in pyrimidine metabolism, exhibit increased sensitivity to treatments that disrupt rRNA transcription, creating a therapeutic vulnerability that can be monitored using Y10B antibody .

What is the role of Y10B antibody in understanding connections between pyrimidine biosynthesis and ribosomal RNA production?

Y10B antibody has been instrumental in elucidating the critical connection between pyrimidine biosynthesis and ribosomal RNA production, particularly in cancer research contexts. Key insights include:

• Metabolic-Ribosomal Crosstalk:

  • Research using Y10B has demonstrated that inhibition of DHODH (dihydroorotate dehydrogenase), a key enzyme in the de novo pyrimidine biosynthesis pathway, directly impacts rRNA transcription

  • The antibody enables precise measurement of 47S pre-rRNA levels following metabolic perturbations

  • Studies revealed that treatment with 0.1 μM brequinar (DHODH inhibitor) significantly reduced UMP, UDP, UTP, and uridine levels, correlating with decreased rRNA production

• Experimental Framework:

  • Researchers first establish baseline rRNA levels in different cell types using Y10B antibody

  • Following metabolic inhibition (e.g., DHODH inhibitors), Y10B is used to quantify changes in rRNA content

  • The effect can be rescued by addition of exogenous uridine, confirming the mechanistic link between pyrimidine availability and rRNA synthesis

  • This approach has revealed that glioblastoma cells, which show higher expression of pyrimidine biosynthesis enzymes compared to normal astrocytes, are particularly vulnerable to this intervention

• Technical Approach to Measuring rRNA Dynamics:

  • Immunofluorescence with Y10B: Visualizes spatial distribution of rRNA and identifies subcellular compartments affected by metabolic inhibition

  • Flow cytometry with Y10B: Provides population-level quantification of rRNA content changes

  • Immunoprecipitation with Y10B: Enables isolation of rRNA for further molecular analysis (sequencing, modification analysis)

• Research Applications:

  • Cancer metabolism studies examining ribosome biogenesis vulnerabilities

  • Drug development targeting nucleolar function through metabolic pathways

  • Biomarker development using rRNA status as an indicator of treatment response

The Y10B antibody thus serves as a critical reagent for establishing mechanistic links between cellular metabolism and ribosome biogenesis, with particular relevance to understanding cancer cell vulnerabilities .

How can Y10B antibody be utilized in multiplexed imaging approaches to study ribosome biogenesis?

Y10B antibody can be effectively incorporated into multiplexed imaging approaches to provide comprehensive insights into ribosome biogenesis processes. Advanced experimental designs include:

• Multi-parameter Immunofluorescence:

  • Y10B is available in multiple conjugated formats including DyLight 350 and biotin-conjugated versions, enabling flexible channel assignment in multiplexed experiments

  • Recommended combinations with Y10B include:

    • Y10B (rRNA) + fibrillarin (dense fibrillar component) + nucleolin (granular component)

    • Y10B + UBF (rDNA transcription) + POLR1A (RNA polymerase I)

    • Y10B + Ki-67 (proliferation) + nucleostemin (pre-ribosomal particles)

  • Optimal fluorophore selection should account for spectral overlap and compensation requirements

• High-Content Imaging Applications:

  • Y10B antibody can be incorporated into high-content screening approaches to assess compounds affecting ribosome biogenesis

  • Automated image analysis parameters for Y10B staining include:

    • Nucleolar area and intensity

    • Nucleolar:nucleoplasmic ratio of Y10B signal

    • Nucleolar number and morphology

    • Co-localization coefficients with other nucleolar markers

• Mass Cytometry (CyTOF) Applications:

  • Y10B has been validated as CyTOF-ready and CyTOF-reported, enabling its incorporation into highly multiplexed mass cytometry panels

  • This allows simultaneous measurement of rRNA content alongside dozens of protein markers

  • Recommended panel design should include cell cycle markers, apoptosis indicators, and ribosome biogenesis regulatory proteins

• Sample Protocol for Triple Immunofluorescence with Y10B:

  • Fix cells with cold methanol (10 minutes at -20°C)

  • Block with 5% BSA in PBS (1 hour at room temperature)

  • Apply Y10B-DyLight 350 (5 μg/ml) and other primary antibodies

  • Incubate overnight at 4°C

  • Counterstain with DAPI if needed

  • Mount and image using a confocal microscope with appropriate filter sets

This approach has been successfully implemented in various cell types, with published examples including co-staining of rRNA (using Y10B-DyLight 350) with alpha-tubulin (DyLight 550) and nuclear counterstaining (DAPI) in Ntera-2 cells .

What are the common challenges when using Y10B antibody and how can they be addressed?

Researchers working with Y10B antibody may encounter several technical challenges. Here are evidence-based solutions to common issues:

• High Background Signal:

  • Problem: Non-specific staining, particularly in the cytoplasm

  • Solutions:

    • Optimize antibody concentration (titrate from 1-10 μg/ml; 5 μg/ml is typically optimal)

    • Increase blocking stringency (5% BSA with 0.1-0.3% Triton X-100)

    • Include RNase inhibitors in all buffers when working with RNA targets

    • For biotin-conjugated versions, use avidin/biotin blocking kit to reduce endogenous biotin signals

    • Include isotype control (Mouse IgG3 Kappa) at equivalent concentration as reference

• Weak or Variable Signal Intensity:

  • Problem: Inconsistent or poor detection of rRNA

  • Solutions:

    • Optimize fixation (cold methanol fixation at -20°C for 10 minutes shows superior results for rRNA epitope preservation compared to aldehyde fixation)

    • Ensure proper permeabilization (0.1% saponin for flow cytometry; 0.1-0.3% Triton X-100 for immunocytochemistry)

    • Extend primary antibody incubation time (overnight at 4°C rather than 1-2 hours at room temperature)

    • Use signal amplification systems for detection (tyramide signal amplification compatible with Y10B)

• Species Cross-Reactivity Issues:

  • Problem: Unexpected results in non-validated species

  • Solutions:

    • While Y10B has broad cross-species reactivity, always validate in new species with appropriate controls

    • Include positive control samples (human or mouse cells) alongside experimental samples

    • For unusual species, consider titrating antibody at higher concentrations (up to 10 μg/ml)

    • Use Western blot validation prior to microscopy-based applications in new species

• Flow Cytometry-Specific Challenges:

  • Problem: Poor separation between positive and negative populations

  • Solutions:

    • rRNA is present in all cells, so expect shift in entire population rather than discrete positive/negative populations

    • Use gentle permeabilization (0.1% saponin preferred over harsher detergents)

    • Include dead cell discrimination dye to exclude compromised cells

    • Optimize compensation when using multiple fluorophores

Based on published protocols, researchers have achieved optimal results using methanol fixation for immunofluorescence and 4% PFA fixation followed by 0.1% saponin permeabilization for flow cytometry applications .

How can Y10B antibody be optimized for detecting changes in rRNA levels under different experimental conditions?

Optimizing Y10B antibody for detecting subtle changes in rRNA levels requires careful experimental design and quantitative approaches:

• Quantitative Immunofluorescence Optimization:

  • Image Acquisition Parameters:

    • Use identical exposure settings across all experimental conditions

    • Ensure signals are within linear detection range (avoid saturation)

    • Collect z-stacks for 3D quantification of nucleolar volume and intensity

    • Include fluorescent intensity calibration beads in experiments

  • Analysis Approach:

    • Measure integrated density rather than mean intensity alone

    • Normalize rRNA signal to nucleolar area or nuclear volume

    • Use automated image analysis software with consistent thresholding parameters

    • Implement watershed segmentation for accurate nucleolar identification

• Flow Cytometry Optimization:

  • Sample Preparation Refinements:

    • Standardize cell numbers (typically 1×10^6 cells/ml)

    • Ensure consistent permeabilization (time and temperature critical)

    • Include RNase inhibitors in all buffers (1 U/μl)

  • Instrument Settings:

    • Establish baseline with untreated cells

    • Create templates with fixed PMT voltages for experimental series

    • Collect sufficient events (minimum 20,000 for subtle changes)

    • Use median fluorescence intensity rather than mean for non-normal distributions

• Experimental Controls to Include:

  • Positive control for decreased rRNA: Actinomycin D treatment (1 μg/ml for 4 hours) inhibits RNA polymerase I

  • Positive control for increased rRNA: Serum stimulation of starved cells (12-24 hours)

  • Treatment time-course to capture transient changes

  • Concurrent measurement of cell cycle phase (DNA content) as rRNA levels vary with cell cycle

• Analytical Considerations:

  • Express results as percent change from control rather than absolute values

  • Consider population heterogeneity (subpopulation analysis may reveal changes masked in bulk measurements)

  • Correlate Y10B signal with functional readouts (proliferation rate, protein synthesis capacity)

Research has shown that inhibition of pyrimidine biosynthesis with 0.1 μM brequinar produces detectable changes in rRNA levels using Y10B antibody, while lower concentrations (0.01 μM) may not produce sufficient changes to be detected. This demonstrates the importance of appropriate dose selection in experimental design .

How is Y10B antibody being applied in research on RNA modifications and epitranscriptomics?

Y10B antibody is increasingly being utilized in the expanding field of RNA modifications and epitranscriptomics, providing insights into how ribosomal RNA modifications affect cellular function:

• Detection of rRNA Modification States:

  • Y10B recognizes ribosomal RNA regardless of most modification states, providing a valuable baseline measurement

  • When used in combination with modification-specific antibodies (e.g., anti-m6A, anti-pseudouridine), Y10B enables normalization of modification levels to total rRNA content

  • This combination approach can identify conditions that alter the ratio of modified to unmodified rRNA

• Experimental Approaches:

  • Sequential Immunoprecipitation:

    • First IP: Use modification-specific antibody to pull down modified RNA

    • Second IP: Use Y10B to determine what proportion of the modified RNA is ribosomal

    • This approach can discriminate between modifications occurring on rRNA versus other RNA species

  • Co-localization Studies:

    • Combine Y10B with antibodies against RNA modification enzymes (e.g., dyskerin, fibrillarin)

    • Quantify spatial relationships between rRNA and modification machinery under various conditions

    • Track dynamic changes in modification patterns during stress responses or disease progression

• Applications in Disease Models:

  • Cancer research: Alterations in rRNA modifications contribute to translational reprogramming

  • Neurodevelopmental disorders: Several ribosomopathies involve defects in rRNA modification

  • Aging studies: Changes in rRNA modification patterns correlate with cellular senescence

• Technical Considerations:

  • RNase treatment controls are essential to confirm specificity of signals

  • When combining with modification-specific antibodies, optimize fixation carefully as some epitopes require specific preservation methods

  • Consider specialized techniques like CARTA (Chromatin-Associated RNA Transcription Assay) combining Y10B with nascent RNA labeling

While Y10B itself does not discriminate between different modification states of rRNA, its broad recognition properties make it an ideal tool for normalizing and contextualizing the findings from modification-specific detection methods in epitranscriptomic research.

What role does Y10B antibody play in understanding the intersection between nucleolar stress and cancer therapeutic response?

Y10B antibody serves as a critical tool for investigating the increasingly important connection between nucleolar stress and cancer therapeutic response:

• Monitoring Nucleolar Stress as a Therapeutic Indicator:

  • Research using Y10B has demonstrated that many cancer therapeutics induce nucleolar stress as part of their mechanism of action

  • Changes in rRNA distribution and levels, as detected by Y10B, correlate with therapeutic response

  • Quantitative analysis of nucleolar morphology and rRNA content using Y10B can serve as early indicators of treatment efficacy, potentially before changes in cell viability are apparent

• Application in Glioblastoma Research:

  • Studies have shown that glioblastoma cells exhibit higher expression of pyrimidine biosynthesis enzymes (DHODH and UMPS) compared to normal astrocytes

  • Y10B antibody has been used to demonstrate that inhibition of pyrimidine biosynthesis causes nucleolar stress specifically in these cancer cells

  • Research indicates that this metabolic vulnerability can be exploited therapeutically, with rRNA transcription inhibition serving as a mechanism to enhance the effectiveness of standard treatments like temozolomide (TMZ)

• Experimental Design for Therapeutic Studies:

  • Baseline Assessment:

    • Use Y10B to establish baseline rRNA levels and nucleolar morphology in patient-derived cancer cells

    • Compare with matched normal tissue controls

  • Treatment Response Monitoring:

    • Apply Y10B in time-course experiments following therapeutic intervention

    • Quantify changes in nucleolar number, size, and rRNA content

    • Correlate with other markers of treatment response (apoptosis, cell cycle arrest)

  • Combination Therapy Evaluation:

    • Use Y10B to assess how metabolic inhibitors (e.g., DHODH inhibitors) affect rRNA status

    • Monitor how these changes sensitize cells to conventional therapies

• Quantitative Parameters for Therapeutic Monitoring:

  • Nucleolar fragmentation index (number of nucleoli per nucleus)

  • Nucleolar segregation (redistribution of rRNA to nucleolar caps)

  • Total cellular rRNA content (by flow cytometry with Y10B)

  • Ratio of mature to precursor rRNA (combining Y10B with precursor-specific probes)

Research has demonstrated that inhibition of the de novo pyrimidine biosynthesis pathway not only impacts rRNA synthesis but can also enhance the DNA damage induced by temozolomide in glioblastoma cells, suggesting a promising therapeutic strategy that can be monitored using Y10B antibody .

How might Y10B antibody be integrated with emerging single-cell technologies?

Y10B antibody holds significant potential for integration with cutting-edge single-cell technologies, enabling unprecedented insights into ribosomal RNA dynamics at cellular resolution:

• Single-Cell RNA Sequencing Applications:

  • CITE-seq Adaptation:

    • Y10B could be adapted for CITE-seq (Cellular Indexing of Transcriptomes and Epitopes by Sequencing) by conjugation to oligonucleotide barcodes

    • This would enable correlation between rRNA content (Y10B binding) and mRNA transcriptome at single-cell resolution

    • Potential to identify cell subpopulations with distinctive ribosomal states

  • Spatial Transcriptomics:

    • Y10B antibody could complement spatial transcriptomics by providing rRNA localization data

    • Implementation through sequential immunofluorescence and in situ hybridization

    • Would enable tissue-level mapping of ribosomal states in heterogeneous samples

• Mass Cytometry (CyTOF) Integration:

  • Y10B has already been validated as CyTOF-ready and CyTOF-reported

  • Integration into panels with up to 40 additional markers enables comprehensive phenotyping

  • Can reveal relationships between rRNA content and various cellular states:

    • Cell cycle phase

    • Differentiation status

    • Stress response activation

    • Metabolic state

• Single-Cell Proteomics Correlation:

  • Combining Y10B immunofluorescence with single-cell proteomics approaches

  • Could establish relationships between rRNA content and translation efficiency

  • Potential to identify thresholds of rRNA content required for specific protein synthesis programs

• Technical Considerations for Single-Cell Applications:

  • Sensitivity optimization is crucial for detecting variations in small cell populations

  • Signal amplification methods may be necessary for rare cell types

  • Careful antibody titration to ensure specificity at the single-cell level

  • Integration of appropriate single-cell controls and standards

The capabilities of Y10B antibody in these emerging technologies are supported by its demonstrated effectiveness across multiple established platforms including flow cytometry, immunofluorescence, and mass cytometry, suggesting strong potential for adaptation to next-generation single-cell analysis methods .

What are the prospects for using Y10B antibody in developing new therapeutic strategies targeting ribosome biogenesis?

Y10B antibody holds significant potential as a research tool for developing novel therapeutic strategies that target ribosome biogenesis, particularly in cancer:

• High-Throughput Screening Applications:

  • Y10B can be implemented in high-content screening approaches to identify compounds that disrupt rRNA synthesis or processing

  • Automated image analysis using Y10B staining can quantify:

    • Changes in nucleolar morphology

    • Alterations in rRNA distribution

    • Reductions in total rRNA content

  • This approach could identify novel small molecules targeting ribosome biogenesis with potential therapeutic applications

• Metabolic Vulnerability Targeting:

  • Research using Y10B has already demonstrated that inhibition of pyrimidine biosynthesis impacts rRNA transcription

  • The antibody can be used to identify additional metabolic pathways that, when inhibited, affect ribosome biogenesis

  • Potential therapeutic strategy: combine metabolic inhibitors with conventional therapies to enhance efficacy through nucleolar stress induction

• Patient Stratification Approaches:

  • Y10B-based assays could identify cancer subtypes with distinctive ribosomal characteristics

  • Potential applications include:

    • Flow cytometry analysis of patient samples to quantify rRNA content

    • Immunohistochemistry on tissue microarrays to assess nucleolar parameters

    • Correlation of these features with treatment response to identify predictive biomarkers

• Mechanistic Understanding for Drug Development:

  • Detailed mechanism studies using Y10B can reveal:

    • How existing drugs affect ribosome biogenesis (potentially explaining off-target effects)

    • Sequence of events during nucleolar stress response

    • Differential sensitivity of various cell types to ribosome biogenesis inhibition

  • These insights can guide development of more targeted therapeutics with improved specificity and reduced toxicity

Research has shown that glioblastoma cells exhibit higher expression of pyrimidine biosynthesis enzymes and greater vulnerability to interventions affecting rRNA synthesis compared to normal astrocytes. Y10B antibody has been instrumental in demonstrating that this differential vulnerability can be exploited therapeutically, potentially enhancing the effectiveness of standard treatments like temozolomide .